



## IBA launches the Fixed IFP™ to enhance Synthera®+ development capabilities at ISRS

*IBA RadioPharma Solutions is presenting the new Fixed IFP™ cassette that allows Synthera®+ to be the only synthesizer compatible with both a disposable and non-disposable cassette systems.*

**Dresden, Germany, May 14<sup>th</sup> 2017** - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for diagnosis and treatment of cancer, today launches the Fixed IFP™ cassette, the new accessory that can be installed on Synthera®+, at the 22<sup>nd</sup> International Symposium on Radiopharmaceutical Sciences held in Dresden, Germany.

The Fixed IFP™ system is an optional Synthera®+ accessory which will be soon commercially available. New radiotracers can be developed with the Fixed IFP™ system and, once the synthesis is well established, the IFP™ disposable cassette should be utilized for routine productions. The Fixed IFP™ increases Synthera®+ development capabilities at reduced cost and in less time since the development is performed on the Fixed IFP™ system with a direct translation to the IFP™ disposable cassette.

**Neva Lazzarova, Head of radiochemistry Solutions at IBA RadioPharma Solutions, commented:** *“There is minimal installation required for the Fixed IFP™ system. Users can switch back and forth between the IFP™ disposable cassette and the Fixed IFP™. Users can easily convert the Synthera®+ from a cassette-based to a non-cassette-based platform. In this way, new radiotracer development is facilitated by eliminating the cost of the disposable cassette and by streamlining the translation from development to routine applications.”*

**Bruno Scutnaire, President at IBA Radiopharma Solutions, commented:** *“Synthera®+ is an accessory based platform allowing our users to start from basic setup and to add functionalities to continuously meet the demands of the future with the unique IFP™ Loader, the Synthera®+ HPLC, the Synthera®+ extension and now the fixed IFP™ for cheaper and simpler development.”*

IBA RadioPharma Solutions will be showcasing the new Synthera®+ family at booth #23 during the ISRS congress. For more information about IBA's new Synthera®+, see: [iba-synthera.com](http://iba-synthera.com)

\*\*\*ENDS\*\*\*



### **ABOUT IBA RADIOPHARMA SOLUTIONS**

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them global solutions, from project design to the operation of their facility.

In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers

### **About Synthera®+**

Synthera®+ is a multi-purpose automated synthesizer capable to produce  $^{18}\text{F}$ -FDG and other compounds ( $^{18}\text{FCH}$ ,  $^{18}\text{FDOPA}$ ,  $^{18}\text{FLT}$ ,  $\text{Na}^{18}\text{F}$ ,  $^{68}\text{Ga}$  peptides ...). This, smallest available module on the market, is designed to accommodate a wide range of radiochemistry processes.

### **About IBA**

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### **For further information please contact:**

#### **IBA**

Rebecca Lo bue

Marketing director

Tel : +32 10 20 12 75

info-cyclo@iba-group.com